These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 34958428)

  • 1. Progression and metastasis of small cell lung carcinoma: the role of the PI3K/Akt/mTOR pathway and metabolic alterations.
    Krencz I; Sztankovics D; Danko T; Sebestyen A; Khoor A
    Cancer Metastasis Rev; 2021 Dec; 40(4):1141-1157. PubMed ID: 34958428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3K/Akt/mTOR signaling orchestrates the phenotypic transition and chemo-resistance of small cell lung cancer.
    Li X; Li C; Guo C; Zhao Q; Cao J; Huang HY; Yue M; Xue Y; Jin Y; Hu L; Ji H
    J Genet Genomics; 2021 Jul; 48(7):640-651. PubMed ID: 34167917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
    Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
    PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.
    Umemura S; Mimaki S; Makinoshima H; Tada S; Ishii G; Ohmatsu H; Niho S; Yoh K; Matsumoto S; Takahashi A; Morise M; Nakamura Y; Ochiai A; Nagai K; Iwakawa R; Kohno T; Yokota J; Ohe Y; Esumi H; Tsuchihara K; Goto K
    J Thorac Oncol; 2014 Sep; 9(9):1324-31. PubMed ID: 25122428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of endoplasmic reticulum stress promotes autophagy and apoptosis and reverses chemoresistance of human small cell lung cancer cells by inhibiting the PI3K/AKT/mTOR signaling pathway.
    Yu XS; Du J; Fan YJ; Liu FJ; Cao LL; Liang N; Xu DG; Zhang JD
    Oncotarget; 2016 Nov; 7(47):76827-76839. PubMed ID: 27765907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma.
    Makinoshima H; Umemura S; Suzuki A; Nakanishi H; Maruyama A; Udagawa H; Mimaki S; Matsumoto S; Niho S; Ishii G; Tsuboi M; Ochiai A; Esumi H; Sasaki T; Goto K; Tsuchihara K
    Cancer Res; 2018 May; 78(9):2179-2190. PubMed ID: 29490947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NDRG2 acts as a negative regulator of the progression of small-cell lung cancer through the modulation of the PTEN-AKT-mTOR signalling cascade.
    Ma Z; Ma Y; Feng J; Xu Z; Cheng C; Qin J; Li S; Jiang J; Kong R
    Toxicol Appl Pharmacol; 2024 Apr; 485():116915. PubMed ID: 38537875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic profiling-based prognostic prediction of patients with advanced small-cell lung cancer in large scale analysis.
    Udagawa H; Umemura S; Murakami I; Mimaki S; Makinoshima H; Ishii G; Miyoshi T; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuchihara K; Goto K
    Lung Cancer; 2018 Dec; 126():182-188. PubMed ID: 30527185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion.
    Chalishazar MD; Wait SJ; Huang F; Ireland AS; Mukhopadhyay A; Lee Y; Schuman SS; Guthrie MR; Berrett KC; Vahrenkamp JM; Hu Z; Kudla M; Modzelewska K; Wang G; Ingolia NT; Gertz J; Lum DH; Cosulich SC; Bomalaski JS; DeBerardinis RJ; Oliver TG
    Clin Cancer Res; 2019 Aug; 25(16):5107-5121. PubMed ID: 31164374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer.
    Jin Y; Chen Y; Tang H; Hu X; Hubert SM; Li Q; Su D; Xu H; Fan Y; Yu X; Chen Q; Liu J; Hong W; Xu Y; Deng H; Zhu D; Li P; Gong Y; Xia X; Gay CM; Zhang J; Chen M
    Clin Cancer Res; 2022 Feb; 28(3):526-539. PubMed ID: 34921019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGFRL1 affects chemoresistance of small-cell lung cancer by modulating the PI3K/Akt pathway via ENO1.
    Chen R; Li D; Zheng M; Chen B; Wei T; Wang Y; Li M; Huang W; Tong Q; Wang Q; Zhu Y; Fang W; Guo L; Fang S
    J Cell Mol Med; 2020 Feb; 24(3):2123-2134. PubMed ID: 31957179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
    Beck JT; Ismail A; Tolomeo C
    Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
    Chen QY; Jiao DM; Wu YQ; Chen J; Wang J; Tang XL; Mou H; Hu HZ; Song J; Yan J; Wu LJ; Chen J; Wang Z
    Oncotarget; 2016 Apr; 7(14):18247-61. PubMed ID: 26919096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway.
    Tripathi SC; Fahrmann JF; Celiktas M; Aguilar M; Marini KD; Jolly MK; Katayama H; Wang H; Murage EN; Dennison JB; Watkins DN; Levine H; Ostrin EJ; Taguchi A; Hanash SM
    Cancer Res; 2017 Aug; 77(16):4414-4425. PubMed ID: 28646020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the phosphoinositide 3-kinase p110-α isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer.
    Wojtalla A; Fischer B; Kotelevets N; Mauri FA; Sobek J; Rehrauer H; Wotzkow C; Tschan MP; Seckl MJ; Zangemeister-Wittke U; Arcaro A
    Clin Cancer Res; 2013 Jan; 19(1):96-105. PubMed ID: 23172887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-Related Polymorphisms in PI3K/Akt/mTOR Pathway Genes Are Predictive of Limited-Disease Small Cell Lung Cancer Treatment Outcomes.
    Jiang W; Zhang W; Wu L; Liu L; Men Y; Wang J; Liang J; Hui Z; Zhou Z; Bi N; Wang L
    Biomed Res Int; 2017; 2017():6501385. PubMed ID: 28280736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resveratrol inhibits viability and induces apoptosis in the small‑cell lung cancer H446 cell line via the PI3K/Akt/c‑Myc pathway.
    Li W; Li C; Ma L; Jin F
    Oncol Rep; 2020 Nov; 44(5):1821-1830. PubMed ID: 32901891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
    Mabuchi S; Kuroda H; Takahashi R; Sasano T
    Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between quantitative perfusion histogram parameters of DCE-MRI and PTEN, P-Akt and m-TOR in different pathological types of lung cancer.
    Zhang B; Zhao Z; Huang Y; Mao H; Zou M; Wang C; Yu G; Zhang M
    BMC Med Imaging; 2021 Apr; 21(1):73. PubMed ID: 33865336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.